Modulators of Glutamatergic Signaling As Potential Treatments of Neuropsychiatric Disorders - Couverture rigide

Couverture rigide

ISBN 10 : 1634834933 ISBN 13 : 9781634834933

Editeur : Nova Science Publishers Inc, 2015

Synopsis

Mounting evidence from preclinical and clinical research suggests that the glutamatergic system is highly involved in the pathophysiology of major neuropsychiatric disorders. All of these scientific activities are a necessary first step, which translates into opportunities in terms of development of new and improved treatment strategies. Glutamate-based research over the last couple of decades has provided novel insights into the pathogenesis of both psychiatric disorders such as treatment resistant depression, bipolar disorder, schizophrenia, PTSD, ADHD and neurological disorders including Alzheimer's dementia, migraine, epilepsy, ALS and neuropathic pain. Recent news developments also indicate glutamate involvement in neurodevelopmental disorders such as autism. In addition to the above, recent discoveries that several novel therapeutic agents like riluzole, memantine, ketamine, topiramate and lamotrigine possess glutamatergic properties as part of their mechanism of action, further boosted the interest of drug development companies and academic research centers to put more effort into investigating novel therapeutically efficacious compounds. Moreover, recent large "real life" clinical studies, such as STAR*D, also looked into disease-associated glutamate genetics and paved the way for the future creation of first individualised pharmacogenetic treatments. The overall purpose of this book is to provide the reader with expert opinions relating to the most up-to-date information on glutamate's role in pathophysiology of neuropsychiatric disorders and current and future glutamatergic treatment strategies. The authors' hope that this contribution will foster future research activities, which are all ultimately aiming to improve quality of life in patients with chronic, psychiatric and neurological disorders, thus enhancing their contribution to society.

A propos du livre

À propos de l'auteur

Born in Belgrade, Serbia. 48 years old. Father of one daughter. Completed Medical School in Belgrade as third best graduate and obtained MD degree in 1992. Finished residency in Psychiatry in 1998 and got board certification in 2002. Started professional career in Pharmaceutical Medical Affairs as CNS Medical Advisor in 1994 and worked on numerous psychiatric and neurological compounds with global pharmaceutical companies for the next 5 years. After obtaining board certification worked for almost 10 years in his own private practice. In the last 4 years working in clinical research field on global clinical trials in various positions dealing with client consultation on clinical development plans and protocol design, medical monitoring and clinical assessments training and psychometric data surveillance. Numerous presentations on innovative approaches in treating psychiatric patients at international congresses (ECNP, CINP). Representative of Advisory Board at European College of Neuropsychopharmacology (ECNP) since 2010. Publications in European and US psychiatric journals including official journal of the European Psychiatric Association, official journal of Collegium Internationale Neuro-Psychopharmacologicum (CINP) and the official journal of the American Neuropsychiatric Association. Member of Editorial Boards of numerous peer-review journals such as Annals of General Psychiatry, Neuropsychiatric Disease and Treatment and Innovations in Clinical Neuroscience.

Détails de l'édition

• Éditeur: Nova Science Publishers Inc
• Date d'édition: 2015
• Langue: anglais
• ISBN 10: 1634834933
• ISBN 13: 9781634834933
• Reliure: Relié
• Numéro d'édition: 1
• Nombre de pages: 184
• Éditeur: Pavlovic MD Zoran M
• Coordonnées du fabricant: Buchpark GmbH; https://www.buchpark.de; ; Krügerweg 1; Trebbin; Brandenburg; 14959; Allemagne